hrp0094p1-12 | Bone A | ESPE2021

Real-world clinical profiles of children with hypophosphatasia (HPP) from the Global HPP Registry

Martos-Moreno Gabriel , Linglart Agnes , Petryk Anna , Kishnani Priya , Rockman-Greenberg Cheryl , Dahir Kathryn , Seefried Lothar , Fang Shona , Ozono Keiichi , Hogler Wolfgang ,

Hypophosphatasia (HPP) is a rare, inherited metabolic disease caused by deficient activity of tissue non-specific alkaline phosphatase (TNSALP). In children, HPP has a heterogeneous clinical presentation, frequently with nonspecific musculoskeletal and systemic manifestations, often leading to misdiagnoses and substantial delays in diagnosis. Data from 323 children with confirmed HPP diagnosis (aged <18 years, ALP activity below the reference range and/or ALPL mut...

hrp0094p2-252 | Growth hormone and IGFs | ESPE2021

Pappalysins and stanniocalcins in prenatal and postnatal life

Martin-Rivada Alvaro , Campillo-Calatayud Ana , Guerra-Cantera Santiago , Sanchez-Holgado Maria , Angel Martos-Moreno Gabriel , Soriano-Guillen Leandro , Pellicer Adelina , Barrios Vicente , Argente Jesus ,

Background: The human growth pattern varies from intrauterine to extrauterine life, with the GH-IGF axis being immature at birth and IGF-I assuming an important role in promoting postnatal growth. The actions of IGF-I are modulated by its interactions with IGFBPs, with this interaction being regulated by pappalysins (PAPP-A, PAPP-A2) and stanniocalcins (STC-1, STC-2), and thus modifying the amount of free IGF-I.Objective:</strong...

hrp0089p3-p135 | Fat, Metabolism and Obesity P3 | ESPE2018

Cut-off for the Follow-up of Obese Children: Cynicism or Realism?

Gallo Francesco , De Quarto Giuditta , Lonero Antonella , Moramarco Fulvio

The majority of treated obese children fail the goals set in the medium-long term or do not show themselves up at the short term follow up. These results, which do not improve even with the proliferation of facilities aimed to the treatment of obesity and of its complications, pose serious questions on how to make the best use of scarce resources available by the National health system. We have visited, between 2013 and 2015, 378 seriously obese children (>2 DS from nation...

hrp0084p3-1160 | Puberty | ESPE2015

Central Precocious Puberty Presented due to Late Started Treatment for Familial Testotoxicosis

Kor Yilmaz , Durmaz Erdem , Bulus Derya , Ceylaner Serdar

Background: Peripheral precocious puberty (GnRH independed): precocious development of secondary sexual characteristics may also be caused by mechanisms that do not involve activation of pulsatile GnRH secretion. Familial male-limited precocious puberty, also known testotoxicosis is a rare dominant form of gonadotropin independent precocity caused by constitutively activating mutations of the human LH choriogonadotropin receptor (LHCGR). If do not treat with appropriate drugs ...

hrp0086wg7.4 | ESPE Paediatric Endocrine Nurse Specialists and Allied Health Professionals Working Group (PENS) | ESPE2016

Poster Review

Kirouac Nicole

Background: Pediatric Endocrine Nurses are experts in caring for children with Endocrine conditions. Many nurses do not have the confidence, knowledge and technical skill set to produce poster presentations that allow them to share this expertise.Objective and hypotheses: This session will give Pediatric Endocrine Nurses an opportunity to hear how a poster presentation can be developed, from an idea to the final product. Nurses will feel empowered to tak...

hrp0082wg2.1 | Global paediatric Endocrinology and Diabetes | ESPE2014

Technological Horizon for the Treatment of Diabetes

Phillip Moshe

The daily treatment of pediatric patients with diabetes is challenging for patients, parents and medical teams. This is probably the reason why most patients all over the world do not meet the targets of glucose control defined by world organizations like ISPAD, EASD and the ADA as the safe zone for preventing complications, extending life expectancy and improving quality of life. New emerging technologies are in the pipeline of both academic centers and industry that promise ...

hrp0089p3-p122 | Diabetes &amp; Insulin P3 | ESPE2018

Challenges in Educating New Onset Type 1 Diabetes Mellitus Patients: Can the Use of a Tablet be the Answer?

Aisenberg Javier , Rosini Lynda , Haugh Jeanette , Mathus Susan , De Vito Michele , Brennan Ingrid , Ghanny Steven

Background: Educating patients and families on the management of Type 1 Diabetes Mellitus (DM) has always been a challenge. Some endocrinologists educate patients and families with new onset Type 1 DM in the inpatient setting, while others have tried to do this process as an outpatient given the changes in the limits of inpatient coverage. Given the challenges in the education process, we must find new and innovative ways to educate patients and families efficiently in order t...

hrp0086p1-p45 | Adrenal P1 | ESPE2016

Polymorphisms Analyze in Gene CYP21A2 Gene Associated with Congenital Adrenal Hyperplasia

Jorgens Prado Mayara , Maria Dornelles da Silva Claudia , Grandi Tarciana , Martins de Castro Simone , Kopacek Cristiane , Lucia Rosa Rossetti Maria

Congenital adrenal hyperplasia is an autosomal recessive inborn error of metabolism due to impaired activity of one enzyme required for cortisol biosynthesis. Steroid 21-hydroxylase (21OH) deficiency is the cause in more than 90% of the patients. The 21OH is encoded by the CYP21A2 gene located on the chromosome 6 in the region known as the RCCX module. Due to the high homology and tandem-repeat organization of the RCCX module, this region of the genome is subjected to...

hrp0086p1-p120 | Bone &amp; Mineral Metabolism P1 | ESPE2016

Practicalities of Bisphosphonate use in UK Paediatric Tertiary Centres

Price Victoria , Ramakrishnan Renuka , Burren Christine , Dharmaraj Poonam

Background: On reviewing practical aspects of intravenous bisphosphonate use in our tertiary Children’s Hospital, we noted disparity between departments who prescribed these drugs. This included issues pertinent to patient safety and hospital management, e.g. the need for overnight admission for the first infusion, blood tests and monitoring for adverse events (AEs). We therefore decided to survey the practices of other tertiary Paediatric Endocrinology Centres.<p cla...

hrp0082s10.1 | Childhood Obesity: Challenges in Management | ESPE2014

The Metabolically Healthy Obese Child

Molnar Denes

Background: Recent interest has focused on a unique subgroup of overweight and obese individuals who have normal metabolic features (MHO) despite increased BMI. According to the WHO obesity is considered a disease itself. In the light of the WHO statement it is most strange to speak about healthy and unhealthy obesity. Nevertheless, we all know that a certain portion of obese persons are free from some (most frequently investigated) obesity-related metabolic consequences.<...